ASHP
  • Program
  • Registration
  • ASHP Spotlight
  • Midyear Coverage
  • Awards and Events
  • ASHP Marketplace
  • Meeting Info
  • Previews
Topics
  • ASHP Spotlight
  • Midyear Coverage
  • Awards and Events
  • ASHP Marketplace
  • Meeting Info
  • Previews
Resources
  • Program
  • Registration
Facebook iconTwitter iconLinkedIn iconInstagram icon
December 7, 2021

Be Part of the Solution to the Opioid Epidemic

How pharmacists can tailor outpatient OUD treatment regimens.


Cherry Jackson and Krystal Riccio
Cherry Jackson and Krystal Riccio

Opioid use disorder (OUD) is a common disease that responds well to drug therapy. But the nation’s healthcare enterprise largely fails to deliver these medications to patients who struggle with the disorder, says Krystal Riccio, associate professor of pharmacy practice at Roseman University of Health Sciences in Henderson, Nevada.

“There’s a lot of evidence surrounding the benefits of opioid agonists for maintenance therapy,” Riccio said. “Despite having effective treatment options available, a mere 20% of patients with opioid use disorder actually receive medication therapy.”

During the Midyear 2021 on-demand session “Road to Recovery: Caring for Persons Living with Opioid Use Disorder in an Ambulatory Care Setting,” Riccio demonstrated how pharmacists can tailor outpatient OUD treatment regimens for their patients, using opioid agonists for detoxification and maintenance therapy and opioid antagonists for overdose reversal and relapse prevention.

Riccio said the goal of OUD treatment is “to maintain the physical, psychological, and social well-being of the individual.” She said the benefits of this approach is that it keeps patients safer no matter where they are in the recovery process.

Session co-presenter Cherry W. Jackson, professor of pharmacy at Auburn University and professor of psychiatry and behavioral neurobiology at the University of Alabama, described physiological effects of opioid use. She noted that OUD is hard to treat, in part, because opioids tap into neurologic reward pathways and alter brain chemistry.

“Opioid use disorder is a medical illness, and it requires evidence-based treatment,” she emphasized. “Every individual has a unique road to recovery. And we need to meet the person where they are and utilize harm reduction and treatment options to suit the needs of the individual.”

Nearly 500,000 people in the United States died from an opioid overdose from 1999 through 2019, according to the Centers for Disease Control and Prevention (CDC). In the 12 months ending in May 2020, the CDC reported a record high of 81,000 overdose deaths, largely attributed to synthetic opioids. Deaths surged starting in March 2020 with the arrival COVID-19 pandemic.

Riccio speculated that some people with OUD died because no one was nearby to witness the overdose and reverse it with naloxone or get other help.

“One of the biggest concerns that we had during the pandemic, with so much social isolation, ... was overdose deaths related to having to use alone,” she said.

Both presenters touted the benefits of harm reduction strategies, including pharmacist dispensing of naloxone, to help stem overdose deaths.

Riccio also said pharmacists can help reduce the stigma around OUD by rethinking how they talk about the disease.

She pointed out that even the seemingly innocuous phrase “medication assisted treatment,” which is used in federal regulatory language about OUD treatment, creates a perception that OUD differs from other illnesses that respond to drug therapy.

“This is the only disease state or condition that we use this terminology in,” Riccio explained.

For comprehensive information on how pharmacists can help stem the opioid epidemic and help patients who struggle with OUD, visit the Feb. 15, 2021, AJHP theme issue on opioid use disorders.

Featured Stories
ASHP announces new Leadership Center and Membership Group
Sponsored by ASHP
ASHP announces new Leadership Center and Membership Group
Geospatial Tools Offer Fresh Perspective on Patient Care
Sponsored by ASHP
Geospatial Tools Offer Fresh Perspective on Patient Care
More Content
Close Up Hand Holding Covid 19 Vaccine 2021 08 28 03 48 08 Utc
ASHP Midyear 2021
FDA, CDC Experts Share COVID-19 Vaccine Progress
December 8, 2021
Thomas Lodise and Michael Rybak
ASHP Midyear 2021
Trough Levels Don’t Cut It for Vancomycin Dosing in Seriously Ill Patients
December 8, 2021
Getty Images 1344197992
ASHP Midyear 2021
Anti-Racism and Its Role in Achieving Health Equity
December 8, 2021
Getty Images 638044582
ASHP Midyear 2021
Don’t Get Caught Sleeping on 340B, Experts Say
December 8, 2021
Cyrine Haidar and Shannon Manzi
ASHP Midyear 2021
Pharmacogenomic Testing Can Benefit Children and Families
December 8, 2021
Brenda Jensen and Jerald Ovesen
ASHP Midyear 2021
Big Changes Coming From USP and NIOSH
December 8, 2021
Tyler Vest
ASHP Midyear 2021
New Research Brings Changes to the Medication-Use Process
December 8, 2021
Terri Jorgenson and Lisa Kearney
ASHP Midyear 2021
An All Hands on Deck Approach for Mental Health and Pain Care
December 8, 2021
Cheyenne Frazier and Karen Gunning
ASHP Midyear 2021
Transgender Care Is Patient Care
December 8, 2021
From left: Andre D. Harvin, Patricia C. Kienle, and Clinton L. Meachum
ASHP Midyear 2021
Thursday’s Virtual Midday Symposia
December 8, 2021
Getty Images 1313783716
ASHP Midyear 2021
Highlights from 10th Annual Pharmacy Forecast Unveiled at Midyear
December 7, 2021
Jao Tribute Mdn
ASHP Midyear 2021
Remembering Joseph A. Oddis, a Giant in Pharmacy
December 7, 2021
ASHP
Facebook iconTwitter iconLinkedIn iconInstagram icon
© 2023 Ascend Media. All rights reserved.